Neuropsychopharmacologic treatment of depression and other neuropsychiatric disorders in HIV-infected individuals

CNS Spectrums

Volumn 8, Issue 1, 2003, Pages 59-63

  Repetto, Martin J ^a   Evans, Dwight L ^c   Cruess, Dean G ^c   Gettes, David R ^c   Douglas, Steven D ^b   Petitto, John M ^a  

^a UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

^c NONE

Author keywords

[No Author keywords available]

Indexed keywords

AMFEBUTAMONE; ANTIBIOTIC AGENT; ANTIDEPRESSANT AGENT; ANTIRETROVIRUS AGENT; CARBAMAZEPINE; COTRIMOXAZOLE; DELAVIRDINE; DESIPRAMINE; DEXAMPHETAMINE; EFAVIRENZ; FLUOXETINE; IMIPRAMINE; INDINAVIR; METHYLPHENIDATE; MIRTAZAPINE; NEFAZODONE; PAROXETINE; PLACEBO; PRASTERONE; PROTEINASE INHIBITOR; PSYCHOSTIMULANT AGENT; PSYCHOTROPIC AGENT; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAQUINAVIR; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; TRICYCLIC ANTIDEPRESSANT AGENT; UNINDEXED DRUG; VALPROIC ACID; VENLAFAXINE;

ADRENERGIC ACTIVITY; AGITATION; ANTICHOLINERGIC EFFECT; ANXIETY DISORDER; ASTHENIA; CLINICAL TRIAL; DEPRESSION; DISEASE ASSOCIATION; DRUG EFFICACY; EXTRAPYRAMIDAL SYMPTOM; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INSOMNIA; MENTAL DISEASE; MIXED LYMPHOCYTE REACTION; NEUROPSYCHIATRY; PRIORITY JOURNAL; PSYCHOPHARMACOLOGY; REVIEW; SEDATION; SEROTONIN SYNDROME; SIDE EFFECT; XEROSTOMIA; ACQUIRED IMMUNE DEFICIENCY SYNDROME; CONTROLLED CLINICAL TRIAL; PSYCHOLOGICAL ASPECT; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME;

AIDS DEMENTIA COMPLEX; ANTIDEPRESSIVE AGENTS; DEPRESSIVE DISORDER; HIV INFECTIONS; HUMANS; PSYCHOTROPIC DRUGS; RANDOMIZED CONTROLLED TRIALS; TREATMENT OUTCOME;

EID: 0037256060     PISSN: 10928529     EISSN: None     Source Type: Journal    
DOI: 10.1017/S1092852900023464     Document Type: Review

References (47)

1. Carney RM, Freedland KE, Eisen SA, Rich MW, Jaffe AS. Major depression and medication adherence in elderly patients with coronary artery disease. Health Psychol. 1995;14:88-90.
2. Patterson TL, Semple SJ, Temoshok LR, et al. Stress and depressive symptoms prospectively predict immune change among HIV-seropositive men. HIV Neurobehavioral Research Center Group. Psychiatry. 1995;584:299-312.
3. Frasure-Smith N, Lesperance F, Talajic M. Depression and 18-month prognosis after myocardial infarction. Circulation. 1995;91:999-1005.
4. Rovner BW, German PS, Brant LJ, et al. Depression and mortality in nursing homes. JAMA. 1991;265:993-996.
5. Elliott AJ, Russo J, Roy-Byrne PP. The effect of changes in depression on health related quality of life (HRQoL) in HIV infection. Gen Hosp Psychiatry. 2002;24:43-47.
6. Evans DL, Staab J, Ward H, et al. Depression in the medically ill: management considerations. Depress Anxiety. 1996;4:199-208.
7. Rabkin JG, Rabkin R, Harrison W, Wagner G. Effect of imipramine on mood and enumerative measures of immune status in depressed patients with HIV illness. Am J Psychiatry. 1994;151:516-523.
8. Elliot AJ, Karina KK, Bergam K, et al. Randomized, placebo-controlled trial of paroxetine versus imipramine in depressed HIV-positive outpatients. Am J Psychiatry. 1998;155:367-372.
9. Younai FS, Marcus M, Freed JR, et al. Self-reported oral dryness and HIV disease in a national sample of patients receiving medical care. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2001;92:629-636.
10. Rabkin JG, Rabkin R, Wagner G. Effects of fluoxetine on mood and immune status in depressed patients with HIV illness. J Clin Psychiatry. 1994;55:92-97.
11. Zisook S, Peterkin J, Goggin KJ, et al. Treatment of major depression in HIV-seropositive men. HIV Neurobehavioral Research Center Group. J Clin Psychiatry. 1998;59:217-224
12. Rabkin JG, Wagner G, Rabkin R. Fluoxetine treatment for depression in patients with HIV and AIDS: a randomized, placebo-controlled trial. Am J Psychiatry. 1999;156:101-107.
13. Rabkin JG, Wagner G, Rabkin R. Effects of sertraline on mood and immune status in patients with major depression and HIV illness: an open trial. J Clin Psychiatry. 1994;5510:433-439.
14. Ferrando SJ, Goldman JD, Charness WE. Selective serotonin reuptake inhibitor treatment of depression in symptomatic HIV infection and AIDS: improvement in affective and somatic symptoms. Gen Hosp Psychiatry. 1997;19:89-97.
15. Ferrando SJ, Rabkin JG, de Moore GM, Rabkin RR. Antidepressant treatment of depression in HIV-seropositive women. J Clin Psychiatry. 1999;60:741-746.
16. Grassi B, Gambini O, Graghentini, et al. Efficacy of paroxetine for treatment of depression in the context of HIV infection. Pharmacotherapy. 1997;30:70-71.
17. Elliot AJ, Karina KK, Bergam K, et al. Antidepressant efficacy in HIV-serpositive outpatients with major depressive disorder: an open trial of nefazadone. J Clin Psychiatry. 1999;60:226-231.
18. DeSilva KE, Le Flore DB, Marston BJ, Rimland D. Serotonin syndrome in HIV-infected individuals receiving antiretroviral therapy and fluoxetine. AIDS. 2001;15:1281-1285.
19. Tseng AL, Foisy MM. Significant interactions with new antiretrovirals and psychotropics. Ann Pharmacother. 1999;33:461-473.
20. Ereshefsky L, Dugan D. Review of the pharmacokinetics, pharmacogenetics, and drug interaction potential of antidepressants: focus on venlafaxine. Depress Anxiety. 2000;12(suppl 1):30-44.
21. Hesse LM, von Moltke LL, Shader RI, Greenblatt DJ. Ritonavir, efavirenz, and nelfinavir inhibit CYP2B6 activity in vitro: potential drug interactions with bupropion. Drug Metab Dispos. 2001;29:100-102.
22. Elliott AJ, Roy-Byrne PP. Mirtazapine for depression in patients with human immunodeficiency virus. J Clin Psychopharmacol. 2000;20:265-267.
23. Fernandez F, Levy JK, Samley HR, et al. Effects of methylphenidate in HIV-related depression: a comparative trial with desipramine. Int J Psychiatry Med. 1995;25:53-67.
24. Wagner GJ, Rabkin JG, Rabkin R. Dextroamphetamine as a treatment for depression and low energy in AIDS patients: a pilot study. J Psychosom Res. 1997;42:407-411.
25. Wagner GJ, Rabkin R. Effects of dextroamphetamine on depression and fatigue in men with HIV: a double-blind, placebo-controlled trial. J Clin Psychiatry. 2000;61:436-440.
26. Rabkin JG, Wagner GJ, Rabkin R. A double-blind, placebo-controlled trial of testosterone therapy for HIV-positive men with hypogonadal symptoms. Arch Gen Psychiatry. 2000 Feb;57141-147; discussion 155-156.
27. Wagner G, Rabkin J, Rabkin R. Exercise as a mediator of psychological and nutritional effects of testosterone therapy in HIV+ men. Med Sci Sports Exerc. 1998;30:811-817.
28. Rabkin JG, Ferrando SJ, Wagner GJ, Rabkin R. DHEA treatment for HIV+ patients: effects on mood, androgenic and anabolic parameters. Psychoneuroendocrinology. 2000;251:53-68.
29. Rabkin JG, Wagner GJ, Rabkin R. A double-blind, placebo-controlled trial of testosterone therapy for HIV-positive men with hypogonadal symptoms. Arch Gen Psychiatry. 2000;57:141-147; discussion 155-156.
30. Moog C, Kuntz-Simon G, Caussin-Schwemling C, Obert G. Sodium valproate, an anticonvulsant drug, stimulates human immunodeficiency virus type 1 replication independently of glutathione levels. J Gen Virol. 1996;77(pt 9):1993-1999.
31. Maggi JD, Halman MH. The effect of divalproex sodium on viral load: a retrospective review of HIV-positive patients with manic syndromes. Can J Psychiatry. 2001;46:359-362.
32. Hugen PW, Burger DM, Brinkman K, et al. Carbamazepine-indinavir interaction causes antiretroviral therapy failure. Ann Pharmacother. 2000;34:465-470.
33. Tran JQ, Gerber JG, Kerr BM. Delavirdine: clinical pharmacokinetics and drug interactions. Clin Pharmacokinet. 2001;40:207-226.
34. Berbel Garcia A, Latorre Ibarra A, Porta Etessam J, et al. Protease inhibitor-induced carbamazepine toxicity. Clin Neuropharmacol. 2000;23:216-218.
35. Parenti DM, Simon GL, Scheib RG, et al. Effect of lithium carbonate in HIV-infected patients with immune dysfunction. J Acquir Immune Defic Syndr. 1988;1:119-124.
36. Rabkin JG, Ferrando SJ, Lin SH, Sewell M, McElhiney M. Psychological effects of HAART: a 2-year study. Psychosom Med. 2000;62:413-422.
37. Fumaz CR, Tuldra A, Ferrer MJ, et al. Quality of life, emotional status, and adherence of HIV-1-infected patients treated with efavirenz versus protease inhibitor-containing regimens. J Acquir Immune Defic Syndr. 2002;29:244-253.
38. Low-Beer S, Chan K, Yip B, et al. Depressive symptoms decline among persons on HIV protease inhibitors. J Acquir Immune Defic Syndr. 2000;23:295-301.
39. Hriso E, Kuhn T, Masdeu JC, Grundham M. Extrapyramidal symptoms due to dopamine blocking agents in patients with AIDS encephalopathy. Am J Psychiatry. 1991;148:1558-1561.
40. Sewell DD, Jeste DV, Atkinson JH, et al. HIV-associated psychosis: a study of 20 cases. San Diego HIV Neurobehavioral Research Center Group. Am J Psychiatry. 1994;151:237-242.
41. Singh AN, Golledge H, Catalan J. Treatment of HIV-related psychotic disorders with risperidone: a series of 21 cases. J Psychosom Res. 1997;42:489-493.
42. Zirulnik L. Pilot study with clozapine in patients with HIV-associated psychosis and drug-induced parkinsonism. Mov Disord. 1999;14:128-131.
43. Wagner GJ, Rabkin JG, Rabkin R. A comparative analysis of standard an alternative antidepressants in the treatment of human immunodeficiency virus patients. Compr Psychiatry. 1996;37:402-408.
44. Breitbart W, Rosenfeld BD, Passick SD, et al. The undertreatment of pain in ambulatory AIDS patients. Pain. 1996;65:243-249.
45. Fernandez F, Levy JK, Mansell PW. Response to antidepressant therapy in depressed persons with advanced HIV infection [abstract]. Paper presented at: the Annual Meeting of the International Conference on AIDS; June 4-9, 1989; Canada.
46. Satel SL, Nelson JC. Stimulants in the treatment of depression: a critical overview. J Clin Psychiatry. 1989;50:241-249.
47. Piscitelli SC, Burstein AH, Chaitt D, Alfaro RM. Indinavir concentrations and St. John's wort. Lancet. 2000;355:547-548.